Chemokines as therapeutic targets in cardiovascular disease: the road behind, the road ahead

H Noels, C Weber, RR Koenen - Arteriosclerosis, Thrombosis, and …, 2019 - Am Heart Assoc
With the incidence and impact of atherosclerotic cardiovascular disease and its clinical
manifestations still rising, therapeutic options that target the causal mechanisms of this …

Targeting CXCR1 and CXCR2 receptors in cardiovascular diseases

K Dhayni, K Zibara, H Issa, S Kamel… - Pharmacology & …, 2022 - Elsevier
CXCR1 and CXCR2 chemokine receptors, mainly activated by interleukin 8 (IL-8 or CXCL8),
are expressed in a variety of cells including, leukocytes, fibroblasts, endothelial cells, and …

The roles of neutrophils linking periodontitis and atherosclerotic cardiovascular diseases

RA Irwandi, ST Chiesa, G Hajishengallis… - Frontiers in …, 2022 - frontiersin.org
Inflammation plays a crucial role in the onset and development of atherosclerosis.
Periodontitis is a common chronic disease linked to other chronic inflammatory diseases …

Where the action is—leukocyte recruitment in atherosclerosis

C Mauersberger, J Hinterdobler… - Frontiers in …, 2022 - frontiersin.org
Atherosclerosis is the leading cause of death worldwide and leukocyte recruitment is a key
element of this phenomenon, thus allowing immune cells to enter the arterial wall. There, in …

Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration

AM Manyara, P Davies, D Stewart, CJ Weir, AE Young… - bmj, 2024 - bmj.com
Randomised controlled trials often use surrogate endpoints to substitute for a target outcome
(an outcome of direct interest and relevance to trial participants, clinicians, and other …

Macrophage migration inhibitory factor (MIF)-based therapeutic concepts in atherosclerosis and inflammation

D Sinitski, C Kontos, C Krammer… - Thrombosis and …, 2019 - thieme-connect.com
Chemokines orchestrate leukocyte recruitment in atherosclerosis and their blockade is a
promising anti-atherosclerotic strategy, but few chemokine-based approaches have …

CXCR1 and CXCR2 inhibition by ladarixin improves neutrophil-dependent airway inflammation in mice

MS Mattos, MR Ferrero, L Kraemer… - Frontiers in …, 2020 - frontiersin.org
Rationale Increased IL-8 levels and neutrophil accumulation in the airways are common
features found in patients affected by pulmonary diseases such as Asthma, Idiopathic …

Impact of immunity on coronary artery disease: an updated pathogenic interplay and potential therapeutic strategies

N Laera, P Malerba, G Vacanti, S Nardin, M Pagnesi… - Life, 2023 - mdpi.com
Coronary artery disease (CAD) is the leading cause of death worldwide. It is a result of the
buildup of atherosclerosis within the coronary arteries. The role of the immune system in …

[HTML][HTML] Targeting the chemokine network in atherosclerosis

Y Yan, M Thakur, EPC van der Vorst, C Weber… - Atherosclerosis, 2021 - Elsevier
Chemokines and their receptors represent a potential target for immunotherapy in chronic
inflammation. They comprise a large family of cytokines with chemotactic activity, and their …

CXCR2 chemokine receptor–a master regulator in cancer and physiology

G Lazennec, K Rajarathnam, A Richmond - Trends in Molecular Medicine, 2024 - cell.com
Recent findings have modified our understanding of the roles of chemokine receptor CXCR2
and its ligands in cancer, inflammation, and immunity. Studies in Cxcr2 tissue-specific …